Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
Fresh from IPO, obesity drug developer BioAge hits a hurdle
pharmaphorum December 9, 2024
It has only been a few weeks since BioAge made its Nasdaq debut via a $198 million IPO, and it has already suffered a setback with its main drug candidate.
The Richmond, California-based start-up has discontinued a phase 2 trial of its obesity drug azelaprag as a monotherapy and in combination with Eli Lilly’s blockbuster weight-loss therapy Zepbound (tirzepatide) after seeing signs of potential liver damage in patients.
Various subjects enrolled into the STRIDES trial showed elevations in liver transaminase enzymes – a sign of liver inflammation – “without clinically significant symptoms,” said BioAge in a statement. There were no increases in transaminases in a control group receiving tirzepatide alone.
“Patient safety is our top priority in the conduct of...
Today's Sponsors
Today's Sponsor